Coherus BioSciences Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Coherus BioSciences de 51.2% y 15% por año respectivamente. Se prevé que el BPA crezca en un 53.3% al año. Se espera que la rentabilidad financiera sea de 57.7% en 3 años.

Información clave

47.4%

Tasa de crecimiento de los beneficios

53.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	30.2%
Tasa de crecimiento de los ingresos	15.0%
Rentabilidad financiera futura	57.7%
Cobertura de analistas	Good
Última actualización	06 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:8C5 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	445	37	N/A	N/A	7
12/31/2025	358	-15	N/A	N/A	7
12/31/2024	261	60	N/A	N/A	6
3/31/2024	302	-59	-154	-153	N/A
12/31/2023	257	-238	-176	-175	N/A
9/30/2023	211	-217	-230	-262	N/A
6/30/2023	182	-264	-213	-245	N/A
3/31/2023	183	-271	-225	-256	N/A
12/31/2022	211	-292	-246	-241	N/A
9/30/2022	239	-279	-231	-193	N/A
6/30/2022	276	-230	-180	-143	N/A
3/31/2022	304	-210	-121	-93	N/A
12/31/2021	327	-287	-39	-37	N/A
9/30/2021	364	-232	-90	48	N/A
6/30/2021	395	-165	-60	82	N/A
3/31/2021	443	-76	-16	142	N/A
12/31/2020	476	132	139	154	N/A
9/30/2020	489	162	113	139	N/A
6/30/2020	487	181	125	146	N/A
3/31/2020	435	145	84	99	N/A
12/31/2019	356	90	15	28	N/A
9/30/2019	232	-12	-38	-37	N/A
6/30/2019	121	-118	-136	-134	N/A
3/31/2019	37	-185	-184	-183	N/A
12/31/2018	N/A	-209	-160	-159	N/A
9/30/2018	N/A	-196	-143	-142	N/A
6/30/2018	N/A	-196	-143	-141	N/A
3/31/2018	1	-208	-164	-161	N/A
12/31/2017	2	-238	N/A	-200	N/A
9/30/2017	2	-265	N/A	-257	N/A
6/30/2017	165	-122	N/A	-278	N/A
3/31/2017	178	-137	N/A	-250	N/A
12/31/2016	190	-127	N/A	-253	N/A
9/30/2016	199	-104	N/A	-160	N/A
6/30/2016	44	-259	N/A	-158	N/A
3/31/2016	37	-248	N/A	-151	N/A
12/31/2015	30	-223	N/A	-108	N/A
9/30/2015	26	-200	N/A	-147	N/A
6/30/2015	35	-137	N/A	-92	N/A
3/31/2015	33	-103	N/A	-72	N/A
12/31/2014	31	-87	N/A	-24	N/A
9/30/2014	26	-73	N/A	14	N/A
6/30/2014	10	-86	N/A	41	N/A
3/31/2014	6	-70	N/A	37	N/A
12/31/2013	3	-54	N/A	15	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 8C5 sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (0.6%).

Beneficios vs. Mercado: Se prevé que 8C5 sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que 8C5 sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (16.6% al año) de 8C5 crezcan más rápidamente que los del mercado German (5.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 16.6% al año) de 8C5 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 8C5 sea muy elevada dentro de 3 años (57.7%).

Coherus BioSciences Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2026

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Coherus Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Coherus BioSciences, Inc. Provides Earnings Guidance for the Full Year 2023

Recent updates

Coherus BioSciences, Inc. Appoints Rita Karachun to Its Board of Directors

Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Forecast breakeven date moved forward to 2024

First quarter 2024 earnings released: EPS: US$0.91 (vs US$0.95 loss in 1Q 2023)

Coherus BioSciences, Inc. announced that it has received $38.7 million in funding

Coherus BioSciences, Inc. Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI®? (toripalimab-tpzi) with ENB-003 for the Treatment of Ovarian Cancer

Coherus BioSciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting

Coherus BioSciences, Inc., Annual General Meeting, May 29, 2024

Full year 2023 earnings released: US$2.53 loss per share (vs US$3.76 loss in FY 2022)

Forecast breakeven date pushed back to 2026

Coherus BioSciences, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New major risk - Financial position

Coherus BioSciences, Inc. Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million.

Coherus BioSciences, Inc. Presents Positive Phase 2 Clinical Data on Casdozokitug, A First-In-Class IL-27-Targeted Antibody, At the 2024 ASCO GI Cancers Symposium

Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Coherus BioSciences, Inc. Appoints Bryan McMichael as Principal Financial Officer

Coherus BioSciences, Inc. Announces Resignation of McDavid Stilwell as Chief Financial Officer, Effective December 31, 2023

Coherus BioSciences, Inc. Presents Phase 1/2 Clinical Data on Casdozokitug at the 2023 ESMO Immuno-Oncology Congress

Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023

Third quarter 2023 earnings released: US$0.41 loss per share (vs US$1.12 loss in 3Q 2022)

Coherus BioSciences, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Coherus BioSciences, Inc. Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Coherus Biosciences, Inc. Announces Resubmission of Biologics License Application (Bla) Supplement for Udenyca(R) Onbody

FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus BioSciences, Inc Also Announces Completion of Toripalimab FDA Inspections

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Second quarter 2023 earnings released: US$0.49 loss per share (vs US$0.65 loss in 2Q 2022)

Coherus Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Coherus BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Coherus Biosciences, Inc. Announces Appointment of Michael Ryan to Board of Directors

Coherus Launches Yusimry™, A Biosimilar of Humira®

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Coherus BioSciences, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings released: US$0.95 loss per share (vs US$1.24 loss in 1Q 2022)

Full year 2022 earnings released: US$3.76 loss per share (vs US$3.81 loss in FY 2021)

Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$1.12 loss per share (vs US$0.49 loss in 3Q 2021)

Coherus BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology

Coherus to Launch Cimerli (Ranibizumab-Eqrn) in the United States on October 3, 2022

Coherus BioSciences, Inc. Announces Executive Changes

Second quarter 2022 earnings released: US$0.65 loss per share (vs US$0.40 loss in 2Q 2021)

FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity

Coherus BioSciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

Coherus BioSciences Appoints Jill O’Donnell-Tormey to Its Board of Directors, Nominating and Corporate Governance Committee of the Board of Directors

First quarter 2022 earnings released: US$1.24 loss per share (vs US$2.38 loss in 1Q 2021)

Coherus Biosciences, Inc. Appoints Charlie Newton to Board of Directors, Member of Audit Committee

Coherus BioSciences, Inc. to Report Q1, 2022 Results on May 05, 2022

High number of new and inexperienced directors

Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting

Coherus BioSciences, Inc., Annual General Meeting, May 17, 2022

Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Coherus BioSciences, Inc. Appoints Paul Reider as Chief Commercial Officer

Coherus BioSciences, Inc. to Report Q4, 2021 Results on Feb 17, 2022

Coherus BioSciences, Inc. Announces Management Changes

Coherus BioSciences, Inc. Announces U.S. FDA Approval of YUSIMRY

Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Positive Interim Overall Survival Results of CHOICE-01, A Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

Third quarter 2021 earnings released: US$0.49 loss per share (vs US$0.39 profit in 3Q 2020)

Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer

Shanghai Junshi Biosciences Co., Ltd. and Coherus Biosciences, Inc. Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. and Coherus Biosciences, Inc. Announce Positive Interim Results from the Pivotal Study Choice-01